Pallas Capital Advisors LLC Makes New Investment in Sera Prognostics, Inc. (NASDAQ:SERA)

Pallas Capital Advisors LLC purchased a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,851 shares of the company’s stock, valued at approximately $113,000.

Several other institutional investors and hedge funds have also modified their holdings of SERA. Bank of New York Mellon Corp raised its holdings in Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares during the period. Rhumbline Advisers acquired a new stake in shares of Sera Prognostics during the second quarter worth $190,000. American Century Companies Inc. lifted its position in Sera Prognostics by 12.7% in the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after acquiring an additional 2,891 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Sera Prognostics in the 2nd quarter worth $162,000. Finally, The Manufacturers Life Insurance Company bought a new position in Sera Prognostics during the 2nd quarter worth about $68,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Sera Prognostics news, General Counsel Benjamin Jackson sold 7,912 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $6.38, for a total transaction of $50,478.56. Following the sale, the general counsel now directly owns 120,561 shares of the company’s stock, valued at $769,179.18. The trade was a 6.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Joshua Phillips sold 12,163 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the transaction, the director now owns 2 shares of the company’s stock, valued at approximately $12.78. This represents a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 93,215 shares of company stock worth $666,835. 15.80% of the stock is owned by insiders.

Sera Prognostics Price Performance

Shares of Sera Prognostics stock opened at $6.61 on Thursday. The firm has a market cap of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. The stock’s 50-day moving average is $7.44 and its 200-day moving average is $7.31. Sera Prognostics, Inc. has a one year low of $4.98 and a one year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the firm earned ($0.23) EPS. On average, equities analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.